Bayforest Capital’s Gilead Sciences GILD Stock Holding History

Bayforest Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-484	Closed	-$44.7K	–	789
2024 Q4	$44.7K	Buy	+484	New	+$43.6K	0.06%	488

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bayforest Capital's GILD Position: Q1 2025 in Review

Bayforest Capital sold out of Gilead Sciences (GILD) in Q1 2025, closing a stake of 484 shares — an estimated $44.7K sold.

Bayforest Capital first reported a position in GILD in Q4 2024 and held it in 1 quarter. The position peaked at $44.7K in Q4 2024. 2,013 funds tracked by Wall St. Rank hold GILD as of Q1 2025.

Bayforest Capital reported no remaining Gilead Sciences position as of Q1 2025 after selling out during the quarter.
Bayforest Capital sold 484 Gilead Sciences shares in Q1 2025, an estimated $44.7K.
Bayforest Capital first reported a position in Gilead Sciences in Q4 2024 and held it in 1 quarter.
Bayforest Capital's Gilead Sciences position peaked at $44.7K in Q4 2024.
2,013 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2025.

Based on Bayforest Capital's 13F filing for Q1 2025, filed 8 May 2025.